Recombinant activated factor VII - A new promising approach for the treatment of severe peripartum hemorrhage;Rekombinanter faktor VIIa - Eine neue vielversprechende option zur behandlung schwerer peripartaler blutungskomplikationen

Geburtshilfe und Frauenheilkunde

Volumn 66, Issue 9, 2006, Pages 833-840

  Rath, W ^a   Schierbrock, S ^a   Heilmann, L ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Gesundheits und Pflegezentrum Russelsheim   (Germany)

Author keywords

Coagulation disorders; Indications; Peripartal (postpartal) hemorrhage; Recombinant activated factor VII; Safety profile

Indexed keywords

RECOMBINANT ACTIVATED FACTOR 7A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; HEMODYNAMICS; HUMAN; HYSTERECTOMY; MORTALITY; POSTPARTUM HEMORRHAGE; REVIEW;

EID: 33749530930     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924223     Document Type: Review

References (30)

1. Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening postpartum haemorrhage. Br J Anaesth 2005; 94: 592-595
2. Arnheim K. Aktuelle Aspekte zur Prophylaxe und Therapie von Blutungen mit Novo Seven®. 4. Frankfurter Novo-Seven®-Workshop Frankfurt 25.10.2002
3. Boehlen F, Morales MA, Fontana P et al. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Br J Obstet Gynaecol 2004; 111: 284-287
4. Bouwmeester FW, Bolte AC, van Geijn HP. Pharmalogical and surgical therapy of primary postpartum hemorrhage. Curr Pharmaceut Design 2005; 11: 759-773
5. Bouwemeester FW, Jonkhoff AR, Verheijen RH, van Geijn P. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated Factor VII. Obstet Gynecol 2003; 101: 1174-1176
6. Breborowicz GH, Sobieszcyk S, Szymankiewicz M. Efficacy of recombinant activated factor VIIa in prenatal medicine. Arch Perinat medicine 2002; 8: 21-27
7. Bundesärztekammer. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 3. Auflage. Hrsg. vom Vorstand und wiss. Beirat der Bundesärztekammer. Köln: Deutscher Ärzteverlag, 2003
8. Dart BW, Cockerham WT, Torres C et al. A novel use of recombinant factor VIIa in HELLP syndrome. J Trauma 2004; 57: 171-174
9. Eigenbrot CH. Structure, function and activation of coagulation factor VII. Curr. Protein and Peptide Science 2002; 3: 287-299
10. Erhardtsen E. Ongoing NovoSeven® trials. Intensive Care Med 2002; 28: 248-255
11. Heilmann L, Wild C, Hojnacki B, Pollow K. Successful treatment of life-threatening bleeding after cesarean section with recombinant activated factor VII (rF VIIa). Clin and Appl Thromb Haemost 2006 (im Druck)
12. Heuer L, Blumenberg D. Rekombinanter Faktor VIIa (Novo Seven®). Ein Überblick über aktuelle und mögliche zukünftige Indikationen. Anästhesist 2002; 51: 388-399
13. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. The Lancet 1999; 354: 1879
14. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-890
15. Levi M. Safety of recombinant factor VIIa. TATM 2003; 5: 11-14
16. Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-438
17. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rF VIIa) in uncontrolled bleeding: a report by the Israel Multidisciplinary rF VIIa Task Force. J Thromb Haemost 2005; 3: 640-648
18. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa. J Trauma 2003; 55: 886-891
19. Merchant SH, Mathew P, Vanderjagt TJ et al. Recombinant Factor VIIa in the management of spontaneous subcapsular liver hematoma associated with pregnancy. Obstet Gynecol 2004; 103: 1055-1058
20. Moscardo F, Parez F, de la Rubia J et al. Successful treatment of severe intra-abdominal bleeding associated with DIC using recombinant activated factor VII. Br J Haematol 2001; 114: 174-176
21. Pötzsch B, Madlener K, Unkrig C, Müller-Bergbaus G. Therapie mit Blutkomponenten und Plasmaderivaten in der Geburtshilfe. Gynäkologe 1997; 30: 782-789
22. Rath W. Prävention lebensbedrohlicher peripartaler Blutungskomplikationen Frauenarzt 2004; 45: 20-30
23. Roberts HR. Factor VIIa and the safety of treatment. Semin Hematol 2001; 38: 48-50
24. Scherer RU, Giebler RM. Perioperative Gerinnungsstörungen. Anästhesiol Intensivmed Notfallmed Schmerzther 2004; 39: 415-443
25. Segal S, Shemesh IY, Blumental R et al. The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand 2004; 83: 771-772
26. Schweizerische Gesellschaft für Intensivmedizin. Off-label-Indikation von rekombinantem aktiviertem Faktor VII (rFVIIa, Novo Seven®). http://www.swiss-icu.ch/NovoSeven_V07.pdf
27. Sobiesczyk S, Breborowicz GH, Markwitz W et al. Effect of recombinant activated factor VII in a patient in haemorrhagic shock after obstetrical hysterectomy. Ginekol Pol 2002; 73: 230-233
28. Tanchev S, Platikanov V, Karadimov D. Administration of recombinant factor VIIa for the management of massive bleeding due to uterine atonia in the post-placental period. Acta Obstet Gynecol Scand 2005; 84: 402-403
29. Wolberg AS, Geoffrey AA, Monroe DM, Hedner U, Robert HR, Hoffmann M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. BJH 2005; 131: 645-655
30. Zupanic Selek S, Sokolic V, Viskovic T et al. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol 2002; 108: 162-163